| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib JA Woyach, RR Furman, TM Liu, HG Ozer, M Zapatka, AS Ruppert, L Xue, ... New England Journal of Medicine 370 (24), 2286-2294, 2014 | 1335 | 2014 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 995 | 2016 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 944 | 2018 |
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ... Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013 | 816 | 2013 |
| Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia KJ Maddocks, AS Ruppert, G Lozanski, NA Heerema, W Zhao, L Abruzzo, ... JAMA oncology 1 (1), 80-87, 2015 | 636 | 2015 |
| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 596 | 2020 |
| The B-cell receptor signaling pathway as a therapeutic target in CLL JA Woyach, AJ Johnson, JC Byrd Blood, The Journal of the American Society of Hematology 120 (6), 1175-1184, 2012 | 532 | 2012 |
| Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JA Fraietta, KA Beckwith, PR Patel, M Ruella, Z Zheng, DM Barrett, ... Blood, The Journal of the American Society of Hematology 127 (9), 1117-1127, 2016 | 488 | 2016 |
| BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437, 2017 | 476 | 2017 |
| Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 417 | 2019 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 415 | 2018 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 353 | 2021 |
| Ibrutinib treatment improves T cell number and function in CLL patients M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ... The Journal of clinical investigation 127 (8), 3052-3064, 2017 | 348 | 2017 |
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy JA Woyach, K Smucker, LL Smith, A Lozanski, Y Zhong, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 123 (12), 1810-1817, 2014 | 342 | 2014 |
| Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation AD Buhimschi, HA Armstrong, M Toure, S Jaime-Figueroa, TL Chen, ... Biochemistry 57 (26), 3564-3575, 2018 | 303 | 2018 |
| Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) JA Woyach, E Bojnik, AS Ruppert, MR Stefanovski, VM Goettl, ... Blood, The Journal of the American Society of Hematology 123 (8), 1207-1213, 2014 | 258 | 2014 |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ... Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019 | 242 | 2019 |
| Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia F Cervantes-Gomez, B Lamothe, JA Woyach, WG Wierda, MJ Keating, ... Clinical cancer research 21 (16), 3705-3715, 2015 | 238 | 2015 |
| Hypertension and incident cardiovascular events following ibrutinib initiation T Dickerson, T Wiczer, A Waller, J Philippon, K Porter, D Haddad, A Guha, ... Blood, the Journal of the American Society of Hematology 134 (22), 1919-1928, 2019 | 209 | 2019 |
| Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation TM Liu, JA Woyach, Y Zhong, A Lozanski, G Lozanski, S Dong, E Strattan, ... Blood, The Journal of the American Society of Hematology 126 (1), 61-68, 2015 | 191 | 2015 |
